Nivolumab

monoclonal antibody

Identifier: CI-DRUG-00000411
Entity page: /drug/nivolumab ↗
Edges: 2,244

Neighbours: 31 cancers1 genes8 variants10 trials72 approvals
Drawn: 60 of 122 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Nivolumab approved for …APPROVED_FOR100 of 72show fewer
→ approved for	Esophageal Squamous Cell Carcinomasubtype	supports	FDA ORIG	Esophageal Squamous Cell Carcinoma	1	Regulatory	openfda	graph →
→ approved for	Malignant Esophageal Neoplasmcancer

→ approved for

EMA · EU · 2015Melanoma Opdivo as monotherapy or in combination with ipilimumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older.Relative to nivolumab monotherapy, an increase in progression-free survival (PFS) and overall survival (OS) for the combination of nivolumab with ipilimumab is established only in patients with low tumour PD-L1 expression (see sections 4.4 and 5.1). Adjuvant treatment of melanoma Opdivo as monotherapy is indicated for the adjuvant treatment of adults and adolescents 12 years of age and older with Stage IIB or IIC melanoma, or melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection (see section 5.1). Non-small cell lung cancer (NSCLC) Opdivo in combination with ipilimumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising EGFR mutation or ALK translocation. Opdivo as monotherapy is indicated for the treatment of locally advanced or metastatic non-small cell lung cancer after prior chemotherapy in adults. Neoadjuvant treatment of NSCLC Opdivo in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have PD-L1 expression ≥ 1% (see section 5.1 for selection criteria). Neoadjuvant and adjuvant treatment of NSCLC Opdivo, in combination with platinum-based chemotherapy as neoadjuvant treatment, followed by OPDIVO as monotherapy as adjuvant treatment, is indicated for the treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have PD-L1 expression ≥ 1% (see section 5.1 for selection criteria). Malignant pleural mesothelioma (MPM) Opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. Renal cell carcinoma (RCC) Opdivo as monotherapy is indicated for the treatment of advanced renal cell carcinoma after prior therapy in adults. Opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (see section 5.1). Opdivo in combination with cabozantinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (see section 5.1). Classical Hodgkin lymphoma (cHL) Opdivo in combination with doxorubicin, vinblastine and dacarbazine (AVD) is indicated for adults and adolescents 12 years of age and older with previously untreated Stage III or IV classical Hodgkin lymphoma. Opdivo as monotherapy is indicated for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma after autologous stem cell transplant (ASCT) and treatment with brentuximab vedotin. Opdivo in combination with brentuximab vedotin is indicated for the treatment of children 5 years of age and older, adolescents and adults up to 30 years of age with relapsed or refractory classical Hodgkin lymphoma after one prior line of therapy (see section 5.1). Squamous cell cancer of the head and neck (SCCHN) Opdivo as monotherapy is indicated for the treatment of recurrent or metastatic squamous cell cancer of the head and neck in adults progressing on or after platinum-based therapy (see section 5.1). Urothelial carcinoma Opdivo in combination with cisplatin and gemcitabine is indicated for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma. Opdivo as monotherapy is indicated for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum-containing therapy. Adjuvant treatment of urothelial carcinoma Opdivo as monotherapy is indicated for the adjuvant treatment of adults with muscle …

EMA (EU) · approved · 2015-06-19 · Melanoma Opdivo as monotherapy or in combination with ipilimumab is indicated for the treatment of advanced (unresectable or metastatic) me…

—

approved

not mapped

Regulatory

ema

open ↗

Nivolumab predicts response to …PREDICTS_RESPONSE_TO8 of 8
← predicts response to	CD274 Expressionexpression 5 source records aggregated	sensitivity	B	Lung Non-Small Cell Carcinoma,Malignant Neoplasm,Melanoma	5	Curated	civic	graph →
← predicts response to	DNMT3A Mutationother	resistance	B	Malignant Neoplasm	1	Curated	civic	graph →
← predicts response to	KRAS Mutationother	sensitivity	B	Lung Non-Small Cell Carcinoma	1	Curated	civic	graph →
← predicts response to	HLA-DRA EXPRESSIONexpression	sensitivity	B	Cutaneous Melanoma	1	Curated	civic	graph →
← predicts response to	MSH2 Lossdeletion_cna	sensitivity	B	Malignant Neoplasm	1	Curated	civic	graph →
← predicts response to	MLH1 Lossdeletion_cna	sensitivity	B	Malignant Neoplasm	1	Curated	civic	graph →
← predicts response to	STK11 Mutationother	resistance	B	Lung Adenocarcinoma	1	Curated	civic	graph →
← predicts response to	PMS2 K706FS*19indel	sensitivity	C	Glioblastoma	1	Curated	civic	graph →

Nivolumab investigated for …INVESTIGATED_FOR15 of 100show all (up to 200)
→ investigated for	Lung Non-Small Cell Carcinomasubtype 4 source records aggregated	supports	B	Lung Non-Small Cell Carcinoma	4	Curated	civic	graph →
→ investigated for	Malignant Neoplasmcancer_family 3 source records aggregated	supports	B	Malignant Neoplasm	3	Curated	civic	graph →
→ investigated for	Cutaneous Melanomacancer	supports	B	Cutaneous Melanoma	1	Curated	civic	graph →
→ investigated for	Lung Adenocarcinomasubtype	supports	B	Lung Adenocarcinoma	1	Curated	civic	graph →
→ investigated for	Melanomacancer_family	supports	B	Melanoma	1	Curated	civic	graph →
→ investigated for	Transitional Cell Carcinomahistology	unknown	4	Transitional Cell Carcinoma	1	Curated	chembl	graph →
→ investigated for	Head and Neck Squamous Cell Carcinomasubtype	unknown	4	Head and Neck Squamous Cell Carcinoma	1	Curated	chembl	graph →
→ investigated for	Colorectal Neoplasmsubtype	unknown	4	Colorectal Neoplasm	1	Curated	chembl	graph →
→ investigated for	Hodgkin Lymphomahematologic_malignancy	unknown	4	Hodgkin Lymphoma	1	Curated	chembl	graph →
→ investigated for	Neoplasmcancer_family	unknown	4	Neoplasm	1	Curated	chembl	graph →
→ investigated for	Renal Cell Carcinomasubtype	unknown	4	Renal Cell Carcinoma	1	Curated	chembl	graph →
→ investigated for	Melanomacancer_family	unknown	4	Melanoma	1	Curated	chembl	graph →
→ investigated for	Lung Non-Small Cell Carcinomasubtype	unknown	4	Lung Non-Small Cell Carcinoma	1	Curated	chembl	graph →
→ investigated for	Glioblastomasubtype	supports	C	Glioblastoma	1	Curated	civic	graph →
→ investigated for	Skin Neoplasmcancer_family	unknown	3	Skin Neoplasm	1	Curated	chembl	graph →

Nivolumab investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 637show all (up to 200)
→ investigated in trials for	Melanomacancer_family 202 trials (70 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Melanoma	202	Observed	clinicaltrials	graph →
→ investigated in trials for	Lung Non-Small Cell Carcinomasubtype 178 trials (65 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lung Non-Small Cell Carcinoma	178	Observed	clinicaltrials	graph →
→ investigated in trials for	Renal Cell Carcinomasubtype 102 trials (44 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Renal Cell Carcinoma	102	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Neoplasmcancer_family 76 trials (22 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Neoplasm	76	Observed	clinicaltrials	graph →
→ investigated in trials for	Solid Neoplasm 70 trials (21 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Solid Neoplasm	70	Observed	clinicaltrials	graph →
→ investigated in trials for	Hepatocellular Carcinomasubtype 65 trials (18 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Hepatocellular Carcinoma	65	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Colorectal Neoplasmsubtype 56 trials (23 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Colorectal Neoplasm	56	Observed	clinicaltrials	graph →
→ investigated in trials for	Head and Neck Squamous Cell Carcinomasubtype 52 trials (18 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Head and Neck Squamous Cell Carcinoma	52	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Lung Neoplasm 52 trials (23 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Lung Neoplasm	52	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Gastric Neoplasm 42 trials (17 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Gastric Neoplasm	42	Observed	clinicaltrials	graph →
→ investigated in trials for	Hodgkin Lymphomahematologic_malignancy 38 trials (16 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Hodgkin Lymphoma	38	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Pancreatic Neoplasm 37 trials (12 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Pancreatic Neoplasm	37	Observed	clinicaltrials	graph →
→ investigated in trials for	Clear Cell Renal Cell Carcinoma 33 trials (20 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Clear Cell Renal Cell Carcinoma	33	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Solid Neoplasm 32 trials (14 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Solid Neoplasm	32	Observed	clinicaltrials	graph →
→ investigated in trials for	Cutaneous Melanomacancer 30 trials (16 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Cutaneous Melanoma	30	Observed	clinicaltrials	graph →

Nivolumab studied in …STUDIED_INderived10 of 1,426show all (up to 200)
→ studied in	NCT01896999Phase 1/Phase 2 · active not recruiting Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma · 1,426 trials list this drug (493 active)	—	—	Classic Hodgkin Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02465060Phase 2 · active not recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) · 1,426 trials list this drug (493 active)	—	—	Hematopoietic and Lymphoid Cell Neoplasm,Lymphoma,Malignant Solid Neoplasm+2	1	Observed	clinicaltrials	graph →
→ studied in	NCT02595944Phase 3 · active not recruiting Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial) · 1,426 trials list this drug (493 active)	—	—	Lung Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03707808Phase 1/Phase 2 · active not recruiting Intratumoral Injection of Autologous CD1c (BDCA-1)+ myDC, AS01B, and Ipilimumab Plus Systemic Nivolumab · 1,426 trials list this drug (493 active)	—	—	Solid Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT03811015Phase 3 · active not recruiting Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer · 1,426 trials list this drug (493 active)	—	—	not mapped	1	Observed	clinicaltrials	graph →
→ studied in	NCT03866382Phase 2 · recruiting Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors · 1,426 trials list this drug (493 active)	—	—	Malignant Genitourinary System Neoplasm,Large Cell Neuroendocrine Carcinoma,Sarcomatoid Renal Cell Carcinoma+2	1	Observed	clinicaltrials	graph →
→ studied in	NCT04310007Phase 2 · active not recruiting Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer · 1,426 trials list this drug (493 active)	—	—	Malignant Lung Neoplasm,Lung Non-Squamous Non-Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04396821Phase 1/Phase 2 · active not recruiting A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors · 1,426 trials list this drug (493 active)	—	—	Malignant Neoplasm,Malignant Gastric Neoplasm,Malignant Pancreatic Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT04495296Phase 1/Phase 2 · active not recruiting A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors · 1,426 trials list this drug (493 active)	—	—	Malignant Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT04751370Phase 2 · active not recruiting Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer · 1,426 trials list this drug (493 active)	—	—	Malignant Rectal Neoplasm,Rectal Adenocarcinoma	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Paths